• Fatigue response as measured by the Functional Assessment of Chronic Illness Therapy Fatigue Subscale
  

• Anemia response at 3 months
  
• Functional level as measured by the Functional Assessment of Cancer Therapy-General Scale and Brief Fatigue Inventory functional interference score monthly
  
• Symptom distress as measured by the Memorial Symptom Assessment Scale-Short Form and the number of symptoms monthly
  
• Quality of life as measured by the Functional Assessment of Cancer Therapy-General Scale monthly
  
• Survival at 6 months
  
• Adrenal suppression
  
• Toxicity
  

OBJECTIVES:

• Compare the effect of epoetin alfa with or without dexamethasone on the level of cancer-related fatigue measured by the FACIT fatigue subscale, in patients with hormone-refractory prostate cancer.
• Compare the effect of these regimens on increasing hemoglobin levels in these patients.
• Compare the effect of these regimens on palliation of other disease-related symptoms and on functional status and overall quality of life of these patients.
• Compare the survival rate of these regimens in these patients.
• Compare the toxicity profile of these regimens in these patients.
• Determine the incidence of adrenal suppression in these patients after receiving dexamethasone therapy.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to usual fatigue severity on the Brief Fatigue Inventory numerical scale (3-6 vs 7-10) and hemoglobin level (8-10 g/dL vs 10.1-11.9 g/dL). Patients are randomized to 1 of 2 treatment arms.

• Arm I: Patients receive epoetin alfa subcutaneously once a week.
• Arm II: Patients receive epoetin alfa as in arm I and oral dexamethasone once a day.

In both arms, treatment continues for 12 weeks in the absence of unacceptable toxicity.

Quality of life and fatigue are assessed at baseline and then at 4, 8, and 12 weeks.

Patients are followed for 3 years.

PROJECTED ACCRUAL: A total of 282 patients (141 per treatment arm) will be accrued for this study within approximately 3 years.

DISEASE CHARACTERISTICS:

• Histologically confirmed prostate cancer

  • Hormone-refractory disease as evidenced by progression on bone scan or CT scan with a rising prostate-specific antigen

• Prior bilateral orchiectomy OR other primary hormonal therapy (e.g., estrogen therapy or luteinizing hormone-releasing hormone analog [LHRH] and flutamide) with evidence of treatment failure

  • Concurrent continual LHRH agonist therapy (e.g., depot leuprolide or goserelin) required for patients who have not undergone bilateral orchiectomy
• Must have anemia with hemoglobin ≥ 8 g/dL and < 12 g/dL within the past 14 days
• Must be iron replete (i.e., ferritin > 50 ng/mL) within the past 30 days
• Presence of fatigue with usual fatigue severity ≥ 3 on the 0-10 numerical scale of the Brief Fatigue Inventory within the past 14 days

PATIENT CHARACTERISTICS:

Age

• 18 and over

Performance status

• ECOG 0-3

Life expectancy

• Not specified

Hematopoietic

• See Disease Characteristics
• No disseminated intravascular coagulation
• No autoimmune hemolytic anemia

Hepatic

• AST and ALT ≤ 2 times upper limit of normal
• No prior hemochromatosis or iron intolerance

Renal

• Creatinine < 2.5 mg/dL

Cardiovascular

• Adequate blood pressure (i.e., systolic blood pressure < 140 mm Hg and diastolic blood pressure < 90 mm Hg) (treated or untreated)
• No history of thromboembolic events
• No unstable angina
• No poorly controlled cardiac disease

Other

• Fertile patients must use effective contraception
• Able to read, understand, and answer questions on the symptom and quality of life study instruments
• No ongoing chronic hemorrhage (e.g., gross hematuria due to advanced prostate cancer)* NOTE: *Microscopic hematuria allowed
• No acute or subacute illness that may require transfusion
• No gastrointestinal bleeding
• No active systemic infection
• No known or suspected hypersensitivity to human albumin
• No known or suspected hypersensitivity to mammalian cell-derived products
• No uncontrolled diabetes

PRIOR CONCURRENT THERAPY:

Biologic therapy

• More than 30 days since prior epoetin alfa

Chemotherapy

• More than 21 days since prior chemotherapy
• No more than 2 different types of prior chemotherapy regimens for hormone-refractory prostate cancer

Endocrine therapy

• See Disease Characteristics

• More than 30 days since prior corticosteroids for hormone-refractory prostate cancer

  • Episodic use of low-dose steroids for other causes is allowed

Radiotherapy

• More than 21 days since prior radiotherapy
• Concurrent radiotherapy allowed

Surgery

• See Disease Characteristics

Other

• More than 8 weeks since prior blood transfusion
• No concurrent oral or intravenous antibiotics